预约演示
Lilly shines light on protein-protein interaction, inking backloaded $660M Prism drug discovery pact
2023-11-29
多肽偶联药物
Working with Lilly, Prism will use its PepMetics technology to discover small molecule inhibitors
ElisLillyJapanese bioPrism BioLabizing in PPI targets, has landed deals with Boehringer Ingelheim, Merck KGaA and Roche in recent years. In those deals, Prism, which raised an Eisai-backed 1.4 billion yen ($9.5 million) series C round in 2021, provided its library of peptide mimetic small molecules for screening against its partners’ targets in exchange for upfront and success-based payments of undisclosed size.
Prismng with Lilly, Prism will use its PepMetics technology to discover smallBoehringer Ingelheim oMerck KGaArget Rocheted by its partner. Lilly has the Prismn to add up to twoEisai PPI targets to the deal, which features an upfront fee and up to $660 million in milestones.
The PepMeticsLillynoPrismunderpinning the deal is a method for quickly synthesizing peptide mimetic molecules. Working with a library of siLillyains and scaffolds, Prism creates fragments that it combines to form intermediates and ultimately PepMetics molecules. The method enables the generation of large numbers of molecules for screening against drug targets.
A drug candidate co-created by Prism and Eisai, dubbed E7386, is in phase 1/2 development in solid tumors. The molecule is designed to inhibit interactions between β-catenin, a protein deemed “undruggable,” and CBP to suppress tumor growth dependent on Wnt signaling. The phase 1/2 trial is testing the idea that the oral candidate may enhance the effect of a checkpoint inhibitor, namely Merck & Co.’s Keytruda.
PPI dysfunction is implicated iPrismide rEisaiof diseasE7386t only a tiny fraction of the intsolid tumorse targeted by approved drugs, largely because identificatioβ-catenin-like molecules capable of disrupting the proteins hastumoren challenging. Prism’s technology represents an attempt to overcome the barriers to PPI inhibition—and a bid to unlock the potential of a mostly untapped arMerck & Co.gy.Keytruda
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。